Premium
Lithium therapy and cerebrospinal fluid biomarker levels in Alzheimer's disease
Author(s) -
Maruyama Masahiro,
Ishizawa Kota,
Tomita Naoki,
Nemoto Miyako,
Yasuda Hiroyasu,
Ebihara Satoru,
Ohrui Takashi,
Seki Takashi,
Iwasaki Koh,
Okamura Nobuyuki,
Higuchi Makoto,
Yoshida Hiroshi,
Kudo Yukitsuka,
Arai Hiroyuki,
Sasaki Hidetada
Publication year - 2005
Publication title -
geriatrics and gerontology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 57
eISSN - 1447-0594
pISSN - 1444-1586
DOI - 10.1111/j.1447-0594.2005.00302.x
Subject(s) - lithium (medication) , medicine , cerebrospinal fluid , lithium therapy , biomarker , pathological , disease , alzheimer's disease , adverse effect , dose , oncology , bipolar disorder , biochemistry , chemistry
Recent studies suggest that lithium may retard pathological deterioration by inhibiting aberrant phosphorylation of tau in Alzheimer's disease (AD). Here, we describe three cases of AD who were treated with lithium for agitation. However, there was no obvious improvement either in global cognition, agitation or cerebrospinal fluid markers that were thought to reflect Alzheimer's pathology. Increased dosages of lithium were not tolerated by the patients because of adverse effects. It is likely that AD patients do not benefit from lithium therapy as an alternative choice of treatment.